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Xerostomia complaint is very commonly associated to radioactive iodine therapy. Alternatives 
to treat this morbidity can offer better quality of life to patients with thyroid cancer submitted to 
adjuvant iodine therapy. 
Aim: to report on the experience with pilocarpine on the treatment of xerostomia in thyroid cancer 
patients submitted to adjuvant radioactive iodine therapy (RIT). 
Materials and methods: The five patients who met the inclusion criteria received 5mg of pilocarpine, 
3 tid for one week. Side effects of the drug and subjective response to xerostomia complaints after 
treatment were evaluated. 
Design: it is a prospective, non-randomized study. 
Results: Sudoresis was the most frequent side effect of pilocarpine use, followed by fatigue and 
headache. Two patients reported relief of xerostomia using pilocarpine, but only one patient was 
able to tolerate the side effects. 
Conclusions: Pilocarpine seems to relieve xerostomia complaints in thyroid cancer patients because 
it is able to stimulate salivary flow, but the observed side effects made the patients refuse long-term 
therapy continuation.
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INTRODUCTION
Saliva plays an important role in the mouth. Decre-
ased or absent flow of saliva may affect chewing, speech 
and swallowing, and may cause a negative impact on the 
patient’s quality of life. The iodine-concentrating feature 
of salivary glands makes them potential targets during and 
after radioiodine therapy.1
Severe acute complications due to radioiodine the-
rapy are extremely rare. Mid and long-term side effects 
have been well described in the literature; these effects 
include sialadenitis, temporary loss of taste, xerostomia 
and dental caries.1-3
Xerostomia is a dry-mouth sensation reported by 
patients.4 It may be caused by several factors, such as local 
or systemic diseases, drugs, radiation or chemotherapy. 
Alexander et al.2 and Caglar et al.5 respectively reported 
iodine therapy related rates of 42.9% and 54% generally 
one year after therapy. Our studies have shown that 11.2% 
of radioiodine therapy patients report xerostomia throu-
ghout the day (unpublished results).
The treatment of xerostomia is difficult; it involves 
relieving the symptoms by using sugar-free chewing gum, 
frequent hydration, saliva substitutes and sialogogues. Pilo-
carpine is a parasympathomimetic agent with β-adrenergic 
effects that stimulates cholinergic receptors on the surface 
of exocrine glands; it decreases the symptoms of xerosto-
mia. Severe adverse effects are rare, but side effects such 
as sweating, increased urinary frequency and redness 
of the skin are common; these are typically moderate in 
intensity and last for a short period of time.6
The purpose of this study was to describe the 
efficacy and feasibility of pilocarpine for the treatment of 
xerostomia in patients undergoing radioiodine therapy.
PATIENTS AND METHODS
This article is part of a large-scale retrospective 
cross-sectional study - with prospective data-gathering in 
some cases - with the following inclusion criteria: patients 
treated for well-differentiated thyroid carcinoma from 1997 
to 2006, undergoing or not adjuvant radioiodine therapy, 
followed up at the Head & Neck Surgery Outpatient Unit 
of the A. C. Camargo Hospital, to assess possible side-
effects of radioiodine therapy on salivary gland function. 
These criteria yielded 400 patients, of which 184 decided 
to participate in this study and signed a free informed 
consent form approved by the institutional review board 
of the institution (process no. 762/06). Papillary carcinoma 
was present in 180 patients and follicular carcinoma was 
present in four patients. The mean age was 49.9 years 
and the median age was 49 years (25-89 years). Adjuvant 
radioiodine therapy was done in 108 patients (58.7%). 
Xerostomia medication (blood pressure lowering drugs, 
anti-histamine medication, antidepressants) was used by 
78 patients (42.4%). All patients underwent salivary gland 
sialometry and scintigraphy.
Sialometry was done according to the method des-
cribed by Koseki et al.7; the total non-stimulated saliva 
volume was collected in a 15 ml Falcon tube for 5 minutes, 
and the total volume was divided by five to calculate the 
milliliter per minute flow. A citric acid tablet (Cewin®, 
Sanofi-Synthelabo, Brazil) was given to collect the total 
stimulated salivary flow; patients were asked to not chew 
the tablet, and saliva was collected as described above. 
The normal parameters used in this study were those 
published by Jensen et al. (non-stimulated flow > 0.3 ml/
min; stimulated flow > 1.5 ml/min).4
The following inclusion criteria were applied to veri-
fy the efficacy of pilocarpine in the treatment of xerostomia 
in patients submitted to radioiodine therapy: patients that 
underwent adjuvant radioiodine therapy simultaneously 
presenting 1- a complaint of xerostomia, 2- abnormal 
salivary flow values on sialometry,4 and 3- salivary gland 
dysfunction on the visual analysis of scintigraphy. Patients 
with contraindications for pilocarpine, such as asthma, high 
blood pressure, heart diseases, and closed angle glauco-
ma, were excluded. Arterial blood pressure was checked 
before therapy. The treatment consisted of administering 
pilocarpine 5 mg three times a day, as recommended in the 
literature,6 mainly before meals and in the evening, during 
one week. Patients filled in a control questionnaire for side 
effects and reported their symptoms during seven days.
RESULTS
Of 108 patients undergoing adjuvant radioiodine 
therapy, 65.4% (70 patients) reported xerostomia during 
at least part of the day, and 11.2% (12 patients) reported 
this symptom throughout the day. Of these 70 patients, 
only 9 patients met the inclusion criteria for the pilocarpine 
therapy protocol. The mean age of these patients was 52.1 
years, and the median age was 56 years (36-65 years). The 
mean radioiodine irradiation dose was 150 mCi (100 - 450 
mCi). Four of these nine patients were not included in the 
study; three patients had uncontrolled high arterial blood 
pressure. The data on patients included in the pilocarpine 
protocol are summarized in Table 1.
The most commonly reported side effect was swe-
ating, which was present in 4 of 5 patients. Three of 5 
patients reported fatigue and headaches. Increased urinary 
frequency, tearing, shivering, dizziness, and nausea were 
present in 2 of 5 patients. One patient presented an alte-
red arterial blood pressure and tachycardia. Two patients 
reported relief of xerostomia by using pilocarpine; two 
patients reported a significant improvement of dry mou-
th, but one of these patients had several side effects, and 
decided against long-term use of pilocarpine.
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DISCUSSION
Different from external radiotherapy, I131 radio-
iodine therapy does not eliminate completely salivary 
gland secretion; functioning parenchyma is preserved and 
responds to stimuli. Xerostomia is found in 11 to 54% of 
radioiodine therapy patients.2,5 Since well-differentiated 
thyroid tumors have a favorable outcome, it is essential to 
reduce the side effects of radioiodine therapy to preserve 
the quality of life of these patients.
Differently from external radiotherapy, in which 
several studies have demonstrated the efficacy of pilocar-
pine for stimulating salivary glands,8-15 few studies have 
showed the effect of pilocarpine for relieving the symptoms 
of xerostomia resulting from radioiodine therapy. Silbers-
tein16 published the results of a blind controlled study of 
60 patients, in which pilocarpine 5 mg was used every 8 
hours during a week, following radioiodine therapy, to 
avoid I131-associated sialadenitis. This study revealed that 
pilocarpine did not reduce the occurrence of radioactive 
iodine-associated sialadenitis. These results confirmed data 
published by Alexander et al.2 ten years ago, in which no 
significant difference was found between patients that 
were given pilocarpine during radioiodine therapy and 
those that were not.
To demonstrate a further use of pilocarpine, Afra-
mian et al.17 published a study demonstrating the efficacy 
of a single 5 mg dose of pilocarpine to increase stimu-
lated and non-stimulated salivary flow in five patients 
with thyroid cancer who underwent adjuvant radioiodine 
therapy at least three months before the study. The results 
showed a significantly increased stimulated and non-
stimulated salivary flow in four patients; there were no 
changes in the systolic and diastolic blood pressure, the 
pulse or body temperature. Until the present, no study 
on the long-term use of pilocarpine for relieving radioio-
dine therapy-associated xerostomia has been published; 
the tolerability of this drug in patients has also not been 
evaluated.
CONCLUSION
Our study showed that pilocarpine had no positive 
effects for routine use in these patients. The side effects 
with three daily 5 mg doses per week were poorly tolera-
ted by patients with thyroid cancer. Thus, this medication 
is not recommended, as its benefits do not outweigh its 
side effects.
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